SCHEMBL13629197

SCHEMBL13629197

CC(C)(C)N1CCCC(C(F)(F)F)C1

nearest known ligand 0.37

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.37
POLB P06746 1/20 0.36
RXFP1 Q9HBX9 1/20 0.35
HTR7 P34969 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
MAP4K4 O95819 1/20 0.31
KMT2A Q03164 2/20 0.31
MEN1 O00255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13790345 0.87
SCHEMBL14297905 0.87
SCHEMBL21341548 0.87
SCHEMBL18327050 0.83
SCHEMBL2601347 0.83
SCHEMBL2614325 0.83
SCHEMBL25890874 0.79
SCHEMBL25537470 0.79 ALDH1A1 (0.33)
SCHEMBL23153239 0.78
SCHEMBL16087794 0.77 ATM (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230278972-A1 SUBSTITUTED HALOALKYL SULFONANILIDE HERBICIDES FMC CORPORATION 2023-09-07 US disclosed
US-20230278972-A1 SUBSTITUTED HALOALKYL SULFONANILIDE HERBICIDES FMC CORPORATION 2023-09-07 US disclosed
US-20200347071-A1 AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2020-11-05 US disclosed
US-9963447-B2 Substituted 4-azaindoles and their use as GluN2B receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2018-05-08 US disclosed
US-7618971-B2 Mitotic kinesin inhibitors MERCK & CO. INC. (US) 2009-11-17 US disclosed
US-20080027058-A1 Mitotic Kinesin Inhibitors MERCK SHARP & DOHME CORP. 2008-01-31 US disclosed
US-20070293511-A1 Crf Receptor Antagonists and Methods SB PHARMCO PUERTO RICO INC. AND NEUROCRINE BIOSCIENCES, INC., A CORPORATION 2007-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278972-A1 SUBSTITUTED HALOALKYL SULFONANILIDE HERBICIDES CBR3, CBR1, GRHPR GAA 1675/4885POLB 3929/4885RXFP1 557/4885
US-20070293511-A1 Crf Receptor Antagonists and Methods CRHR1, CRHR2, CRH GAA 1986/4885POLB 4702/4885RXFP1 109/4885
US-20200347071-A1 AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS RIPK1, RIPK2, RIPK4 GAA 4168/4885POLB 3389/4885RXFP1 1635/4885
US-20080027058-A1 Mitotic Kinesin Inhibitors KIF5B, KIF2C, KIF23 GAA 1016/4885POLB 498/4885RXFP1 4749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.